Figure 3.

Modeling PTF1A enhancer mutations in human MPCs

(A) qRT-PCR of human MPCs for pancreatic progenitor markers (n = 7–13 independent differentiation experiments per genotype, using 6 PTF1A^enhΔ/enhΔ clones—3 lines with 127 bp and 3 lines with 321-bp deletions, see Figure S2B—and 4 PTF1A^+/+ control lines. Graphs show means ± SEM. Mann-Whitney ^∗p ≤ 0.05, ^∗∗p ≤ 0.01, ^∗∗∗p ≤ 0.001).

(B) Quantification of FACS data for PDX1+ NKX6-1+ stage-4 in vitro derived MPCs (n = 8–10 independent differentiation experiments per genotype; ns, not significant).

(C) Immunofluorescence of human MPCs (stage 4) shows absence of PTF1A in PTF1A^enhΔ/enhΔ lines, without changes in NKX6-1. See also Figure S2.